Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis

Siemens HealthineersSiemens Healthineers and Biogen announced today that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Biogen is a leading biotechnology company with a deep focus on neurological and autoimmune conditions, which for two decades has been at the forefront of delivering therapies to MS patients. Siemens Healthineers aims to enable healthcare providers to meet their current challenges and excel in their respective environments. To execute this strategy in the field of neurology, Siemens Healthineers will cooperate with Biogen and contributes its strength in medical imaging.

"By bringing together the shared expertise of both Siemens Healthineers and Biogen in imaging and neurology, respectively, we seek to develop new measurement tools that meet the particular technical challenges of MS," says Dr. Christoph Zindel, Senior Vice President of Magnetic Resonance Imaging at Siemens Healthineers. "Our shared goal is to create a solution that can be integrated into the existing radiology workflow, so it can become a seamless part of routine care - delivering new and valuable information to treating neurologists, without increasing the cost or burden on the healthcare system."

MRI is routinely used to support physicians in diagnosing MS, measuring disease activity and monitoring response to therapy. Clinicians qualitatively evaluate MRIs by comparing the current MRI to the previous MRI. Numerous studies have demonstrated that quantitative MRI measures may provide additional information about disease prognosis and therapeutic effect, but today quantitative measurement techniques with the precision and sensitivity required for MS are typically only available in the research setting. With the development and validation of automated MRI applications to quantify key markers of MS, including new T2 lesions and brain atrophy, patients could benefit from the availability of enhanced data at the point of care.

"Biogen believes that the availability of high-quality, standardized data at the point of care can lead to a deeper understanding of MS, more informed treatment decisions and, ultimately, improved patient outcomes" says Richard Rudick, MD, Vice President Development Sciences, Biogen. "We also recognize that the ability to generate research-quality data in the course of routine clinical practice can unlock the potential of the health care system to move towards precision medicine."

About Siemens Healthineers
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today's dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and net income of over €2.3 billion and has about 46,000 employees worldwide.

Most Popular Now

Almost All Leading AI Chatbots Show Sign…

Almost all leading large language models or "chatbots" show signs of mild cognitive impairment in tests widely used to spot early signs of dementia, finds a study in the Christmas...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Emotional Cognition Analysis Enables Nea…

A joint research team from the University of Canberra and Kuwait College of Science and Technology has achieved groundbreaking detection of Parkinson's disease with near-perfect accuracy, simply by analyzing brain...

New Recommendations to Increase Transpar…

Patients will be better able to benefit from innovations in medical artificial intelligence (AI) if a new set of internationally-agreed recommendations are followed. A new set of recommendations published in The...

Digital Health Unveils Draft Programme f…

18 - 19 March 2025, Birmingham, UK. Digital Health has unveiled the draft programme for its Rewired 2025 event which will take place at the NEC in Birmingham in March next...

AI System Helps Doctors Identify Patient…

A new study from Vanderbilt University Medical Center shows that clinical alerts driven by artificial intelligence (AI) can help doctors identify patients at risk for suicide, potentially improving prevention efforts...

Smartphone App can Help Reduce Opioid Us…

Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a...

AI's New Move: Transforming Skin Ca…

Pioneering research has unveiled a powerful new tool in the fight against skin cancer, combining cutting-edge artificial intelligence (AI) with deep learning to enhance the precision of skin lesion classification...

Leveraging AI to Assist Clinicians with …

Physical examinations are important diagnostic tools that can reveal critical insights into a patient's health, but complex conditions may be overlooked if a clinician lacks specialized training in that area...

AI can Improve Ovarian Cancer Diagnoses

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...